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Abstract Human telomerase might be associated with malig- 
nant tumor development and could be a highly selective target for 
antitumor drug design. Antisense phosphodiester (ODNs) and 
phosphorothioate (S-ODNs) oligonucleotides were investigated 
for their abilities to inhibit telomerase activity in the HeLa cell 
line. The ODNs and S-ODNs were designed to be complemen- 
tary to nucleotides within the RNA active site of telomerase. As a 
transfection reagent, FuGENE6 was used to enhance the cellular 
uptake of oligonucleotides in cell cultures. The results showed 
that S-ODN-3 (19-mer) encapsulated with FuGENE6 clearly 
inhibited the telomerase activity in HeLa cells, and the inhibitory 
efficiency increased with an increase in the S-ODN-3. However, 
free S-ODN-3 showed no inhibitory activity. On the other hand, 
ODN-3 encapsulated with FuGENE6 had no detectable inhibi- 
tory activity. The encapsulated S-ODNs exhibited higher 
inhibitory activities than the free S-ODNs, and showed sequence 
specific inhibition. Thus, the activities of the S-ODNs were 
effectively enhanced by using the transfection reagent. The 
transfection reagent, FuGENE6, may thus be a potentially useful 
delivery vehicle for oligonucleotide-based therapeutics and 
transgenes, and is appropriate for use in vitro and in vivo. 
© 1999 Federation of European Biochemical Societies. 
Key words. Antisense phosphorothioate oligonucleotide; 
Telomerase; Transfection reagent; HeLa cell 
1. Introduction 
The telomere is a specialized DNA-protein complex, located 
at the eukaryotic hromosome t rminus. In humans and ver- 
tebrates, telomeres consist of hundreds to thousands of tan- 
dem repeats of the hexanucleotide s quence (TTAGGG)n 
[1,2]. The lengths of these repeat racts vary from 15 to 20 
kb in germ line cells, and from 5 to 12 kb in peripheral blood 
leukocytes [3]. They play an important role in cell replication 
by allowing the end of linear DNA to be replicated completely 
[4]. In addition, telomeres are proposed to be responsible for 
chromosome stabilization [5] by protecting the chromosome 
from enzymatic end-degradation a d preventing its fusion 
with other chromosomes. In every cell division cycle, the te- 
lomeres continually shorten by about 50-200 nucleotides, and 
when they reach the critical ength, then the cell stops dividing 
and becomes enescent. This means that maintaining the telo- 
mere at a constant length is necessary for cell immortalization 
and tumor cell division. 
Telomerase is a ribonucleoprotein, i  which the RNA corn- 
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ponent provides the template for the synthesis of telomeric 
repeats (TTAGGG) at the end of the chromosome to main- 
tain the telomere at a constant length [6,7]. Telomerase activ- 
ity can be detected in approximately 85 90% of primary hu- 
man tumors [8] and is probably critical for sustained tumor 
proliferation, although this hypothesis remains in dispute. The 
introduction of a gene encoding an antisense RNA, targeted 
to the telomerase RNA component in the HeLa immortalized 
cell line leads to the proliferation crisis and cell death. Thus, 
the antisense approach seems to be a very attractive means of 
telomerase inhibition as a viable strategy for the suppression 
of tumor growth [9-11]. 
Antisense oligonucleotides have been used to regulate gene 
expression [12 15]. Antisense phosphodiester oligonucleotides 
have been reported to have an inhibitory effect against HIV-1 
[16,17]. However, antisense phosphodiester oligonucleotides, 
in particular, have limited survival in vitro and in vivo, be- 
cause they are rapidly degraded by nucleases present in serum 
and in cells [18,19]. Antisense oligonucleotides with phospho- 
rothioate backbones exhibit several advantages over the other 
forms, including relatively high nuclease resistance and the 
capacity to induce the degradation of the target sequence by 
RNase H [20,21]. Another problem in the use of antisense 
oligonucleotides is their inefficient cellular uptake. They are 
mainly found in endosomes and lysosomes. The use of a de- 
livery vehicle with specific uptake by cells would increase the 
circulation half-life of the oligonucleotides and improve their 
efficacy [22 24]. Liposome delivery addresses both of these 
concerns. Liposome delivery of oligonucleotides to cells in 
vitro has been shown to greatly reduce the effective concen- 
tration as compared to that of the free oligonucleotide [25 
27]. 
Recently, it was reported that the telomerase inhibition by 
peptide nucleic acids (PNA) occurred in a sequence specific 
manner in cell-free systems [28,29]. However, PNAs do not 
appear to serve as substrates for RNase H. 
In this paper, we present a detailed analysis of the inhi- 
bition of telomerase activity by ODNs and S-ODNs designed 
to be complementary to the template region of the telomerase 
RNA (Table 1). We also describe the potency of the trans- 
fection reagent (FuGENE6). 
2. Materials and methods 
2.1. Materials 
Phosphodiester and phosphorothioate oligonucleotides were synthe- 
sized by Boston BioSystems Ltd (MA, USA). The following cationic 
liposomes, which are commercially available transfection reagents, 
were used: FuGENE6 (blended lipid with other compounds in 80% 
ethanol, Boehringer Mannheim, GmbH, Germany), DOTAP (N-[1- 
(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate, 
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Boehringer Mannheim), Tfx-10 (N,N,N',N'-tetramethyl-N,N'-bis(2- 
hydroxyethyl)-2,3-dioleoyloxy-l,4-butanediammonium iodide) and L- 
dioleoylphosphatidyl-ethanolamine (DOPE) in a molar ratio of 1:9 
(Promega, Madison, WI, USA). 
2.2. Cell line 
The HeLa cell line, which expresses a relative high telomerase ac- 
tivity was employed. Cells were cultured in Dulbecco's modified Ea- 
gle's medium (DMEM) containing 10% (v/v) heat-inactivated fetal 
calf serum (FCS). 
2.3. Antisense oligonucleotides 
The ODNs and S-ODNs were synthesized by J.BioS Co. and were 
purified by HPLC. They were designed to have 15- to 23-mer lengths 
and to be complementary to the template (5'-CUAACCCUAAC-3') 
region in the telomerase RNA. S-ODN-1 and ODN-1 are 15-mer 
sequences, which overlap the target sequence from U42 to G56. On 
the basis of ODN-1 (15-mer) the lengths of the other oligomer se- 
quences were elongated by two-base increments towards the 5' end, 
according to the pairing bases of the target (Table 1). 
2.4. Oligonucleotide trans/ection protocol 
Before the transfection, the cells were plated on 6-well plates and 
were incubated until the cells were about 80°/,, confluent. The cells 
were washed with fresh FCS-free DMEM, and 900 btl FCS-free 
DMEM were added into each well prior to transfection. For the 
preparation of the complex of antisense oligomers/transfector, the 
FuGENE6 transfection reagent (Boehringer Mannheim Co.) was di- 
luted with serum-free medium and was incubated for 5 min at room 
temperature. Then, the desired amount of oligomer was added into 
the prepared transfection reagent, and the mixture was incubated for 
15 rain at room temperature to form the transfection complex. The 
final volume of the complex in each sample was 100 btl. 
The complexes (100 gl each) were added dropwise to the prepared 
cell cultures containing 900 btl FCS-free medium, and the solutions 
were mixed gently. A FuGENE6 reagent only control and a normal 
cell control (untreated) were also included. After an incubation for 4 h 
at 37°C, 1 ml of 20% FCS in DMEM was added into each well, to 
make a final FCS concentration of 10%. The cultures were incubated 
for 24 h at 37°C in a humidified incubator with 95% air 15% CO2. 
2.5. Cell extract assay 
The cell extract assay was performed according to the reported 
descriptions [28,30]. Treated cultures were washed once with phos- 
phate-buffered saline (PBS), pelleted at 6000 rpm for 5 min, resus- 
pended in PBS, and pelleted again. Cell extracts were obtained by 
resuspending 10 s cells into 200 btl of lysis buffer (0.5% 3-(3-cholami- 
dopropyl-dimethylammonio)-l-propane-sulfonate (CHAPS), 10 mM 
Tris-HC1, pH 7.5, and 5.1 mM ethylene bis-(oxyethylene-nitrilo) tet- 
ra-acetic acid (EGTA), 5 mM B-mercaptoethanol, 0.1 mM 4-(2-ami- 
noethyl)benzenesulfonyl fluoride (AEBSF), 10% glycerol). The sus- 
pension was mixed and lysed for 30 rain on ice. The lysates were 
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centrifuged at 12000×g for 20 rain at 4°C. A portion (160 pl) of 
the supernatant was collected and aliquoted into four tubes. The 
aliquots (equivalent to 500 cells/gl) were quickly frozen in liquid nitro- 
gen and were stored at -84°C. The telomerase activity in the cell 
extract is stable for at least 6 months at this temperature. 
2.6. Measurement of telomerase activity 
The telomerase activity in the transfected cell extracts was measured 
by using the PCR-based telomere repeat amplification protocol 
(TRAP) [30]. The TS primer (AATCCGTCGAGCAGAGTT) in the 
TRAP Kit (Oncor Inc.) can serve as a telomerase substrate. The 
telomerase in the cell extract adds a number of telomeric repeats 
(GGTTAG) onto the 3' end of the TS oligonucleotide. Then, the 
extended products are amplified by reverse transcription PCR. The 
amounts of the PCR products, which are visualized by polyacrylamide 
gel electrophoresis (PAGE), indirectly represent the telomerase activ- 
ity. 
The HeLa cell extracts were added directly to the TRAP reaction 
mixture (20 mM Tris-HCl, pH 8.3, 1.5 mM MgC12, 63 mM KC1, 
0.05% Tween-20, 1 mM EGTA, 0.01% BSA, 1 gl dNTPs, 1 gl TS 
primer, 1 B1 primer mix, and 0.5 gl (2 units) Taq-polymerase). After 
an incubation for 20 min at 30°C to allow the telomerase to elongate 
the TS primer, the reaction mixtures were immediately heated for 
2 rain at 94°C to inactivate the telomerase and to stop the TS primer 
elongation. Then, a three-step PCR (94°C for 30 s, 50°C for 30 s, and 
72°C for 45 s) was performed for 30 cycles, in which the final step of 
the last cycle was an incubation at 72°C for 2 min. The PCR products 
were analyzed by 10% non-denaturing PAGE. The gels were stained 
by SYBR Green (FMC) and were visualized with a UV transillumi- 
nator (300 nM transillumination) and a FAS-II (Toyobo) image sys- 
tem. 
The telomerase activities were quantified by means of the NIH 
Image 1.55 software. The mean density of each lane in the image 
was measured. The reported ata of the treated samples are expressed 
as percent inhibition relative to the untreated control sample, in which 
the telomerase activity was defined as 100%. The density of the re- 
agent control (no cell extract) was subtracted from the background. 
3. Results and discussion 
Telomerase consists o f  an essential RNA and a few pro- 
teins. The telomerase RNA contains a region complementary  
to the telomere repeats. This special region (3 ' -CAAUCC-  
CAAUG-5 ' )  serves as a template dur ing the synthesis o f  telo- 
meric DNA by te lomerase [30]. Therefore,  the template region 
is deduced to be one of  the active sites in the enzyme, and was 
selected as the target o f  the antisense ol igonucleotides for the 
regulat ion of  the telomerase activity. 
Nor ton  et al. invest igated the inhibit ion of  te lomerase ~tc- 
Table 1 
Sequences of antisense oligonucleotides 
Name Length (mer) 
6O 
Te lomerase  RNA 3' -  GG AAG AGU 
S-ODN- I  / ODN- I  15 5'- 
S-ODN-2 / ODN-2 17 5'- CA 
S-0DN-3 / ODN-3 19 5'- C TCA GTT 
S-0DN-4 / ODN-4  21 5 ' -  TTC TCA GTT 
S-0DN-5 / 0DN-5  23 5' -  CC  TTC TCA GTT 
S -ODN-3- ran  b 19 5' - CAT  ~TG 
S-ODN-3-sen  19 3' - G AGT CAA 
Sequence a 
55 50 45 40 
CAA UCC CAA UCU GUU UU-5' 
GTT AGG GTT AGA CAA -3' 
GTT AGG GTT AGA CAA -3' 
AGG GTT AGA CAA -3' 
AGG GTT AGA CAA -3' 
AGG GTT AGA CAA -3' 
CCT ATC CCG CCT GA 
TCC CAA TCT GTT -5' 
-3 '  
aThe RNA active site and complementary nucleotides within the antisense oligonucleotides are in boldface. 
bThe random sequences (S-ODN-3-ran) with the same base composition as antisense oligomers (S-ODN-3). 
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Fig. 1. Inhibition of telomerase activity by S-ODNs. The TRAP protocol was employed to measure the telomerase activity. In each measure- 
ment, 160 HeLa cell equivalents were used. The PCR products of the telomerase in the gel were visualized by SYBR Green staining. A: Inhibi- 
tion effects were detected using free and encapsulated S-ODN-3, S-ODN-3-sen, and S-ODN-3-ran. Lane 1, untreated control cells; lane 5, nega- 
tive control; lanes 2M, sense and random control oligonucleotides with or without the transfection reagent, FuGENE6; lanes 7 10, treated 
with free S-OND-3. B: Inhibition of telomerase activity by the S-ODN-1-3 encapsulated with transfection reagent, FuGENE6. Lanes 1 and 12, 
untreated control cells; lanes 11 and 19, negative controls (without cell extract added). 
tivity in cell-free systems by S-ODNs [28]. The inhibition by S- 
ODNs in cell-free extracts was due to non-specific binding to 
non-template RNA or protein components, rather than Wat- 
so ,Cr i ck  pairing, because the random S-ODN control could 
also suppress the telomerase activity. The same phenomenon 
was also observed in our laboratory (data not shown). When 
cell-free extracts of HeLa cells were treated with the sense or 
random S-ODNs, telomerase activity was also significantly 
inhibited (even in a dose-dependent manner), due to non-spe- 
cific binding. In common with other DNA and RNA polym- 
erases, it is likely that telomerase also binds DNA substrates 
via association between its protein component and the nega- 
tively charged phosphodiester bonds of DNA, and similar 
interactions might lead to enhanced binding and inhibition. 
S-ODNs are negatively charged and may associate with pro- 
teins in this manner. This suggests that tests of the inhibition 
of telomerase activity by S-ODNs in a cell-free system are not 
suitable. 
The in vitro telomerase activity of the antisense oligonu- 
cleotides was assessed on the basis of their inhibitory effects 
in HeLa cell lines. To clarify the sequence specificity, we tested 
the phosphorothioate oligonucleotides with antisense sequen- 
ces as targets to the nucleotides (11 nucleotides) within the 
RNA active site of telomerase, as well as sense sequences and 
random sequences with the same base composition as the 
antisense oligomers (Table 1). We also evaluated the inhibi- 
tory effects of free ODNs and S-ODNs and those encapsu- 
lated with FuGENE6 on the telomerase activity. 
First, we tested the inhibitory effects on the telomerase ac- 
tivity, using free ODNs and S-ODNs that progressively over- 
lapped the telomerase RNA template region in HeLa cells. 
The HeLa cell line possesses high telomerase activity, which 
presents a linear response with the cell number. The inhibition 
of telomerase activity using oligonucleotides was assayed us- 
ing the tclomerase repeat amplification protocol (TRAP) [31]. 
In this protocol, telomerase extends an oligonucleotide primer 
to form elongation products. These products are then ampli- 
fied by PCR to facilitate their detection. TART affords a 
sensitive and linear response over the range of telomerase 
activity used in these studies, and inclusion of an internal 
amplification strand in each sample permits reproducible 
quantification. 
We could not detect any inhibitory effects on the telomerase 
activity with the free S-ODN-3 at 1 7 gM concentrations in
HeLa cell cultures (Fig. 1A). On the other hand, the free 
ODN-3 was also tested, and showed no inhibitory effects at 
1 7 laM concentrations in the HeLa cell line (data not shown). 
These results suggest hat the negative results on the inhibi- 
tory effect of the free antisense oligonucleotides might be as- 
sociated with poor delivery to HeLa cells. Applications of 
antisense oligonucleotides in vitro and in vivo are hampered 
by several imiting factors, such as oligonucleotide stability, 
cellular uptake, subcellular availability, and other pharmaco- 
kinetic parameters [32-35]. These factors lead to relatively 
poor delivery of the oligomers to the targeted molecular sites, 
and make treatments cost prohibitive. Thus, efficient ransport 
and intracellular delivery are important and fundamental con- 
siderations when developing an effective oligonucleotide-based 
therapy. Liposomally encapsulated antisense oligonucleotides 
have significantly enhanced intracellular delivery, they have 
simultaneously introduced new disadvantages of their own 
[36,37]. Cationic lipids are being used in vitro and in vivo 
for the delivery of oligonucleotides for therapeutic or re- 
searches purpose, and are the vehicles of choice for some 
forms of gene therapy [3842]. Therefore, we evaluated the 
inhibition of telomerase activity by S-ODNs encapsulated 
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with FuGENE6 (non-liposomal formulation) as a transfection 
reagent o enhance the delivery of the oligonucleotides into 
HeLa cells. Every transfection experiment included control 
cells treated with FuGENE6 alone and oligonucleotide alone. 
These additions did not inhibit telomerase activity. 
The encapsulated S-ODN-3 showed the highest inhibitory 
effect on the telomerase activity (87% inhibition at 3 ~tM), and 
the inhibition occurred in a dose-dependent manner (Fig. 1B 
and Table 2). For the control sequences of the sense and 
random oligonucleotides (S-ODN-3-sen and S-ODN-3-ran), 
we could not detect any inhibitory effects on the target elo- 
merase RNA at a 5 ~tM concentration. In this assay system, 
the phosphorothioate oligonucleotides cannot inhibit the telo- 
merase activity because the sense and random phosphoro- 
thioate oligonucleotides, which lacked complementary to
hTR, did not detectably inhibit telomerase activity. These 
results suggest hat the encapsulated S-ODN-3 has a signifi- 
cant advantage over the use of S-ODN alone for delivery into 
HeLa cells and conferred sequence specific inhibition of the 
telomerase activity. However, if a more direct measurement of 
the antisense oligonucleotide binding to targeted telomerase 
RNA can be identified, it should help to clarify the mecha- 
nism of antisense inhibition of telomerase activity. On the 
other hand, the encapsulated ODN-3 (5 gM concentration) 
did not show any inhibitory effects on the telomerase activity 
(data not shown). Furthermore, we examined the inhibition of 
human telomerase activity by S-ODN-3 encapsulated with 
several types of cationic liposomes in HeLa cells. The S- 
ODN-3 encapsulated with FuGENE6 showed higher inhibi- 
tory effects than the S-ODN-3 encapsulated with other cati- 
onic liposomes, DOTAP and Tfx-10 (data not shown). The 
transfection reagent, FuGENE6, has a significant advantage 
over the use of S-ODN alone for delivery of S-ODN into 
HeLa cells. 
The lengths of the S-ODN sequences were studied, and the 
overlapping S-ODNs were used to identify the nucleotides (11 
nucleotides) within the RNA active site of telomerase (Table 
1). S-ODN-1 (15-mer), which is complementary to the telo- 
merase RNA template (C46-C56) as well as its adjacent four 
bases upstream (Table 1) showed weaker inhibitory efficiency 
with only 64% of the telomerase activity inhibited at a 5 gM 
concentration (Table 2). Therefore, when the S-ODN-1 se- 
quence was extended by two bases at its 5' end (the paired 
Table 2 
Inhibition of telomerase activity by S-ODNs encapsulated with Fu- 
GENE6 
Name Length Inhibition (%)~,,c ICs0 (gM) b'c 
1 p,M 3 gM 5 gM 
S-ODN-1 15 42 63 64 1.62 
S-ODN-2 17 36 75 87 1.50 
S-ODN-3 19 59 87 93 0.61 
S-ODN-4 21 25 71 81 1.94 
S-ODN-5 23 13 42 84 2.69 
S-ODN-3-ran 19 7 
S-ODN-3-sen 19 15 
aInhibition (%) represents he percentage of telomerase activity in- 
hibited by S-ODNs, as compared with the untreated HeLa cell cul- 
ture control (expressed as100% telomerase activity). 
bIcs0 represents he concentration f S-ODNs at which 50% of the 
telomerase activity was inhibited. 
CData represent average values for at least three different experi- 
ments. 
bases include U57 and G58 in the target) to form a 17-base 
sequence (S-ODN-2), the inhibition efficiency increased from 
64'70 to 87% (Table 2). Furthermore, while the S-ODN-1 se- 
quence was further elongated for another two bases (A59 and 
G60) in the same direction to form S-ODN-3 (19-mer), an 
obvious increase of telomerase inhibition was observed as 
compared to S-ODN-1 and S-ODN-2, and the telomerase 
activity was inhibited up to 93% at a 5 ~tM concentration. 
The increase of the inhibitory efficacy of S-ODN-3 is not 
entirely dependent on its longer sequence length, because S- 
ODN-4 (21-mer) and S-ODN-5 (23-mer), which are two and 
four bases longer than S-ODN-3 (19-mer), possessed less te- 
lomerase inhibitory activity. Presumably, addition bases of the 
longer S-ODNs offer more potential for non-specific contacts 
in the yield stronger intramolecular secondary structure, 
thereby reducing the likelihood of binding the telomerase tar- 
get. It is known that the phosphorothioate oligonucleotides 
blocked the proliferation HIV-1 in infected cells in a non- 
sequence specific manner [43], probably the inhibition of re- 
verse transcriptase [44,45] and/or the viral entry process 
[46,47]. Our previous tudy of the anti-HIV activities of anti- 
sense oligonucleotides indicated that a phosphorothioate oli- 
gonucleotide targeted to the HIV-1 gag gene was inhibitory, 
and the sense and the random sequence oligomers were also 
able to protect against HIV-1 induced CPE, but their anti- 
HIV-1 activities were weaker than that of the antisense phos- 
phorothioate oligonucleotide (S-ODN-gag-AUG) [48]. Fur- 
thermore, the inhibition of HIV-1 in de novo infected cells 
by the phosphorothioate homooligonucleotides is related 
more to their length than to their sequence [49,50]. These 
results suggest hat S-ODN-3, which progressively overlaps 
the targeted sequence downstream from C46 to G60, might 
induce more significant inhibition in a sequence specific fash- 
ion. 
In conclusion, the antisense phosphorothioate oligonucleo- 
tides (S-ODN-3, 19-mer) complementary to the template re- 
gion of the telomerase RNA showed the greatest inhibition of 
telomerase activity in HeLa cells. The use of the transfection 
reagent, FuGENE6, provides a simple and successful method 
for the intracellular delivery of oligonucleotides. The antisense 
phosphorothioate oligonucleotides encapsulated with Fu- 
GENE6 exhibited higher inhibitory activities than the free 
oligonucleotides, and showed sequence specific inhibition, 
whereas the free antisense phosphorothioate oligonucleotides 
suffered from poor delivery to the HeLa cells. Furthermore, 
the S-ODNs encapsulated with FuGENE6 did not appear to 
be cytotoxic in cell growth rate. The transfection reagent may 
have an advantage over conventional encapsulating liposomes 
for delivery of high levels of oligonucleotides in vitro and in 
vivo. Consequently, these specific antisense phosphorothioate 
oligonucleotides appear to be favorable therapeutic agents for 
cancer. 
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